https://finance.yahoo.com/news/nurexone-provides-corporate-120000076.html

“ExoTherapy”, NurExone’s proprietary Exosome siRNA loaded product, is being developed to recover functionality in patients with traumatic spinal cord injuries read more

Bnei-Brak, Israel–(Newsfile Corp. – June 22, 2022) – NurExone Biologic Inc. (formerly, EnerSpar Corp.) (TSXV: NRX) (“NurExone” or the “Company“) is pleased to announce that, further to its press release of June 15, 2022 announcing the closing of its reverse takeover transaction, it will commence trading on the TSX Venture Exchange (the “TSXV“) under

Calgary, Alberta–(Newsfile Corp. – June 15, 2022) – NurExone Biologic Inc. (formerly, EnerSpar Corp.) (TSXV: NRX) (the “Company“) is pleased to announce that it has completed its previously announced business combination transaction (the “Transaction“) with NurExone Biologic Ltd. (“NurExone“). read more

Calgary, Alberta–(Newsfile Corp. – May 17, 2022) – EnerSpar Corp. (TSXV: ENER) (FSE: 5E0) (“EnerSpar” or the “Company“) and NurExone Biologic Ltd. (“NurExone“) are pleased to announce that the TSX Venture Exchange (“TSXV” or the “Exchange“) has conditionally accepted the previously announced reverse takeover transaction (the “RTO“) of EnerSpar pursuant to a

Calgary, Alberta–(Newsfile Corp. – March 15, 2022) – EnerSpar Corp. (TSXV: ENER) (FSE: 5E0) (“EnerSpar” or the “Company“) is pleased to announce it has entered into an arrangement agreement (the “Arrangement Agreement“) dated March 10, 2022, between the Company and 1222150 B.C. Ltd (the “Subsidiary“), a wholly-owned subsidiary of the Company, with

Calgary, Alberta–(Newsfile Corp. – August 30, 2021) – EnerSpar Corp. (TSXV: ENER) (FSE: 5E0) (“EnerSpar” or the “Company“) and Nurexone Biologic Ltd. (“Nurexone“) are pleased to announce that they have entered an arms-length letter of intent dated 23 August 2021 (amended) pursuant to which EnerSpar and Nurexone propose to complete